On 28 August 2026 FDA approved Mimrylo (rusfertide) for polycythemia vera — the first hepcidin-mimetic peptide medicine. The mechanism is iron restriction, and it is a case study in engineering an unusable hormone into a drug.
Avexitide is a GLP-1 receptor antagonist — the same target as semaglutide, the opposite direction. In August 2026 it cut severe hypoglycaemic events by 55% in Phase 3. The pharmacology is a lesson in why direction matters.
A listed telehealth company with 2.9 million subscribers is preparing to sell peptides, and is already running stability testing on BPC-157. What that says about where this category is heading — and what the coverage keeps getting wrong.
At the FDA’s July 2026 compounding panel, six peptides passed and one failed: emideltide (DSIP). Why that single rejection is the most revealing vote of all.
Samsung Biologics has bid CHF 1.46bn for Swiss peptide CDMO PolyPeptide. A sober look at what the deal says about manufacturing capacity, and what it doesn’t.
Lilly’s retatrutide passed TRIUMPH-2 and TRIUMPH-3 in July 2026 — but missed on cardiovascular events, and the FDA filing slipped to Q1 2027. An honest read.
An FDA panel recommended six of seven peptides for the 503A compounding list on 23-24 July 2026. That is not approval. What the vote did and did not do.
Which peptides Andrew Huberman has said he personally uses — pinealon, BPC-157, sermorelin — and what the primary literature actually shows about each.
Bryan Johnson has trialed CJC-1295, HGH, tirzepatide, cerebrolysin, epithalon, follistatin and BPC-157. A sourced look at what he measured, kept, and dropped.
Joe Rogan says he uses BPC-157 and TB-500 to heal injuries. We fact-check the claims against the actual literature — what holds up, what doesn’t.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
